Allergy Therapeutics (AGY) — Cash Flow Reinvestment Rate
Allergy Therapeutics (AGY) has a Cash Flow Reinvestment Rate of 0.31x as of December 2021, reinvesting GBX1.15 Million (capex GBX1.15 Million ) from operating cash flow of GBX3.71 Million. Check how high is Allergy Therapeutics's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Allergy Therapeutics Cash Flow Reinvestment Rate (2003–2021)
Historical reinvestment intensity for Allergy Therapeutics across 11 annual periods. Explore AGY debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Allergy Therapeutics (2003–2021)
Year-by-year capital reinvestment analysis for Allergy Therapeutics. For live market cap and broader valuation context, see AGY market cap.
| Year | Reinvestment Rate | Total Reinvested (GBX) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 0.61x | GBX5.20 Million | GBX8.52 Million | GBX2.56 Million | ▲ +48.3% |
| 2020 | 0.41x | GBX5.06 Million | GBX12.28 Million | GBX2.55 Million | ▼ -62.6% |
| 2019 | 1.10x | GBX6.16 Million | GBX5.60 Million | GBX2.81 Million | ▼ -94.3% |
| 2017 | 19.34x | GBX3.44 Million | GBX178.00K | GBX1.50 Million | ▲ +5436.9% |
| 2015 | 0.35x | GBX1.09 Million | GBX3.12 Million | GBX1.09 Million | ▼ -15.5% |
| 2014 | 0.41x | GBX898.00K | GBX2.17 Million | GBX898.00K | ▲ +22.4% |
| 2013 | 0.34x | GBX821.00K | GBX2.43 Million | GBX821.00K | ▼ -22.9% |
| 2012 | 0.44x | GBX1.26 Million | GBX2.88 Million | GBX1.26 Million | ▼ -56.1% |
| 2010 | 1.00x | GBX1.70 Million | GBX1.70 Million | GBX1.70 Million | ▲ +150.2% |
| 2004 | 0.40x | GBX760.00K | GBX1.91 Million | GBX760.00K | ▲ +105.8% |
| 2003 | 0.19x | GBX406.00K | GBX2.10 Million | GBX406.00K | — |